Gemcitabine plus S‐1 vs S‐1
Serious adverse events · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus S‐1 changes serious adverse events compared with S‐1 (very low certainty).
1 finding from 1 review
- Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes onlyRR 1.05 [0.15, 7.1]1 study · 90 participantsVery low